Articles tagged with Vaccine Development
Researchers developed a Zika vaccine that safely protects both mother and fetus from the virus. However, pregnancy weakens the immune response, requiring a higher dose of vaccination to be effective.
Researchers have developed a new biotechnology platform to produce safer 'hybrid' viruses for vaccines and diagnostics against mosquito-borne diseases. The Binjari virus, inert to humans, is used to create 'dangerous-looking' viruses like Zika and dengue that cannot grow in humans or animals.
Researchers at UMSOM are testing a combined Shigella-ETEC vaccine to offer protection against diarrheal diseases, which cause millions of deaths worldwide. The vaccine has been developed with $4.5 million funding from Emergent BioSolutions.
A new method has been developed to accelerate the development of protein therapeutics by utilizing a cell-free system for glycosylation. This approach enables researchers to quickly discover and understand glycosylation pathways, leading to faster medicine creation and potentially opening up new avenues for treating diseases.
Eastern equine encephalitis virus is a deadly mosquito-borne illness that has existed for centuries, with a particularly deadly year in the US in 2019. Current research efforts focus on developing vaccines and treatments, but challenges include limited funding and difficulties in reaching target populations.
OHSU researchers have been awarded $2.1 million to develop new adjuvants that can enhance immune responses against infectious diseases. The goal is to create a range of adjuvants that can be used with different vaccines to protect against various pathogens.
Dr. Bruce Alberts will receive the 2020 John Edward Porter Legacy Award for his commitment to scientific research and education. The award recognizes his efforts to promote science as inquiry and improve science education in primary and secondary schools.
Dr. Kathleen Neuzil's pivotal research informed global vaccine policy, saving millions worldwide. As a member of the National Academy of Medicine, she will continue to shape public health policy.
Researchers have identified promising new strategies to counteract infection and develop effective vaccines. The vaccine targets both the offending microbe and its tick carrier to prevent Lyme disease.
The study found that almost complete immune capacity in the gut had developed as early as 14 weeks, with cells from both innate and adaptive immune systems present. This discovery could lead to the development of new maternal vaccines and a better understanding of the risk of autoimmune diseases.
The US FDA has approved a new smallpox vaccine called JYNNEOS, which is non-replicating and can be used to protect against both smallpox and monkeypox diseases. The vaccine developed by Bavarian Nordic was shown to have a superior immune response compared to the existing ACAM2000 vaccine.
MIT researchers have developed a delivery system that makes RNA vaccines more powerful, triggering efficient protein production and boosting immune response. The nanoparticles also activate an immune signaling pathway, provoking T cells to attack cancer cells and infectious agents.
A new type of vaccine that can be stored at warmer temperatures has been developed for Chikungunya, a disease that causes crippling headache and joint pain. The vaccine candidate has shown exceptionally promising results in animal studies, setting the stage for a future vaccine to combat the disease.
Replacing seasonal vaccines with universal ones could avert over 17 million cases and 251,000 hospitalizations per year. States with high hospitalization costs and elderly populations would experience the greatest economic benefits.
The University of Maryland School of Medicine has been awarded a $200 million contract from the National Institute of Allergy and Infectious Diseases to develop and test new influenza vaccines. The research aims to protect against emerging flu strains and improve seasonal vaccines.
A recent study reveals that dengue virus mutations in its E protein can render vaccines and treatments ineffective. The findings also suggest that lab-adapted strains may not accurately represent clinical strains, highlighting the need for further research.
Researchers at Penn Medicine have developed a vaccine that protects against genital herpes, with almost all animal subjects exposed to the virus showing sterilizing immunity. The vaccine stimulates three types of antibodies to block the virus from entering cells and ensure innate immune system protective functions are not turned off.
A Wistar team is advancing a synthetic DNA technology called DNA-encoded monoclonal antibodies (DMAbs) to combat multidrug-resistant Pseudomonas aeruginosa. The researchers have demonstrated the effectiveness of DMAbs in controlling infection in mice, paving the way for further development and clinical testing.
Researchers are developing a vaccine to counteract opioid addiction, with the goal of helping people stop the addiction and regain control of their lives. The vaccine, consisting of one shot and two boosters, aims to develop antibodies against opioids, alleviating symptoms and potentially saving lives during overdose.
Researchers developed a DNA vaccine for Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) that completely protects against lethal infection in ferrets. The vaccine induces both neutralizing antibody response and multifunctional T cell immunity.
A new study has gained insights into the mechanism of vaccine-induced T cell immunity, shedding light on the regulation, gene expression, and metabolic pathways of T cells. The discovery of a marker, TfR1, suggests that T cell immunity depends on specific metabolites.
Researchers have achieved a major breakthrough in developing a thermally stable TB vaccine using a technique called ensilication, which protects vaccine components from heat damage. This innovation has the potential to improve the effectiveness and accessibility of vaccines globally, particularly in remote areas.
Researchers at Yale University have developed a promising combination immune therapy to dramatically reduce the recurrence of genital herpes. The prime-and-pull strategy involves a vaccine and medicated cream that work together to block the virus from spreading.
A novel RSV vaccine candidate, DS-Cav1, has shown early promise in a Phase 1 clinical trial, prompting large increases in RSV-neutralizing antibodies. The vaccine induced a sevenfold increase in neutralizing antibody levels after a single dose of 50 μg and a 12-fold surge with a dose of 150 μg.
A large-scale analysis of over 200,000 individuals found no positive correlation between vaccinations and the development of multiple sclerosis. MS patients were statistically less likely to receive vaccinations before diagnosis than comparator groups.
A new, more effective influenza vaccine is being tested in the US, aiming to improve seasonal flu shot effectiveness. The vaccine uses adjuvants to enhance protection against infection, with a technology designed by artificial intelligence.
Researchers developed a new vaccine, NOMV-FHbp, which induced higher levels of protective antibodies than licensed vaccines against five of six bacterial strains. The vaccine has the potential to extend coverage to infants and toddlers, who are at high risk of developing meningococcal disease.
Researchers developed a cancer vaccine technology using live, attenuated pathogens as vectors. The novel vaccine causes the bacteria to self-destruct once they've done their job, making it safe for human use. This innovation has potential applications in treating various cancers and infectious diseases.
Researchers developed a novel mouse model of intestinal parasite infection that mimics human disease, offering protection against Cryptosporidium infection. The model uses a naturally occurring species of mouse Cryptosporidium and demonstrates the importance of T cells and interferon-gamma in immune response.
Researchers have discovered an antibody that can bind to a highly conserved region of the virus, potentially neutralizing all GII.4 strains of norovirus. This breakthrough is a significant step forward in the development of an effective vaccine for the dreaded stomach virus.
Researchers identified factors contributing to placental transfer of antibodies, including a preference for NK-activating antibodies that activate natural killer cells. This knowledge can be used to develop more effective maternal vaccines and deliver them during pregnancy to protect newborns from serious diseases like polio.
Researchers sequenced DNA of over 2,000 Group A Streptococcus samples from 22 countries to identify common genetic targets for a global vaccine. The study reveals that current vaccine candidates may have limited coverage in low-income areas where Strep A is most prevalent.
Scientists have developed a new single vaccination approach that simultaneously protects against both influenza and pneumococcal infections, overcoming the limitations of current vaccines. The approach combines vaccines targeting different components of the virus and bacteria, inducing enhanced cross-protective immunity.
A broadly effective dengue vaccine is still a substantial challenge due to the disease's complexity. However, experts suggest that rethinking existing concepts and developing live attenuated vaccines could lead to more effective solutions.
Researchers at Princeton University developed a mouse model of hepatitis C by introducing human proteins that allow the virus entry to liver cells. The study found that small mutations in a liver cell protein significantly impact viral replication in mice and humans.
The NIH has awarded four Cooperative Research Centers to develop vaccines against syphilis, gonorrhea, and chlamydia. The centers will focus on identifying vaccine candidates that could lead to safe and effective treatments for these diseases.
Researchers have developed an orally administered hepatitis B vaccine that is both effective and safe. The new vaccine uses a technique called 3D imaging to understand how the vaccine behaves in the body, leading to improved efficacy and reduced side effects.
A new study suggests that vaccination could reduce the impact of white-nose syndrome in bats by providing immunity against the fungus Pseudogymnoascus destructans. Bats immunized against Pd were less likely to develop WNS or die from the disease in two initial scientific trials.
A $10.7 million NIH grant will fund the establishment of a Gonorrhea Vaccine Cooperative Research Center, with Oregon State University's Aleksandra Sikora working to develop a vaccine against gonorrhea, a sexually transmitted disease that causes significant harm if untreated or improperly treated.
Researchers developed a novel recombinant vaccine called NIPRAB that shows strong immunization against Nipah virus in animal models. The live vaccine is safe in mice, eliciting a strong antibodies response and reacting to similar viruses like Hendra and Rabies.
A potent and safe vaccine protects against MERS, a viral infection with a 35% mortality rate in 27 countries. The new vaccine platform targets specific cells without causing lung damage, offering a promising strategy for enhancing vaccine safety and potency.
InDevR to showcase VaxArray technology at the BIO International Convention, leveraging NIH SBIR/STTR funding. The company has a proven track record of translating scientific ideas into commercial products.
Researchers at UTMB are developing rapid-acting vaccines and broad-spectrum treatments for Ebola and Marburg, two highly-lethal hemorrhagic fever viruses considered Tier 1 pathogens. The $35M NIH grant will support the creation of new vaccines and treatments to address high mortality rates ranging from 50-90%.
Experts discuss ongoing research on improving seasonal influenza vaccines and developing a universal vaccine for long-term protection against multiple seasonal and pandemic influenza viruses. Recent scientific advances have provided unprecedented momentum toward this goal.
Pediatric health researchers offer new insights for RSV vaccine development, highlighting the importance of type 1 interferons in infants' immune response. The study suggests strategies to enhance type 1 interferon responses and improve existing vaccines, offering hope for prevention of severe RSV disease in infants.
An international research team developed a new technique to analyze vast amounts of data from tiny amounts of newborn blood, revealing molecular changes in the first week of life. The study provides a common developmental pathway for this period, enabling further understanding of newborn health and vaccine impact.
A global team of scientists has mapped a newborn's life development in unprecedented detail, revealing thousands of changes over the first week. This breakthrough study could transform our understanding of health and disease in babies, and inform the development of optimized protective measures, including vaccines.
Researchers have pioneered a technique to analyze tiny amounts of newborn blood, providing the most detailed accounting to date. The study establishes a common developmental pathway for the first week of a newborn's life, offering insights into newborn health and the impact of vaccines.
A Yale team isolated antibodies from mice bitten by mosquitoes and found a protein, AgBR1, that exacerbates Zika infection. Blocking this protein with an antiserum reduced Zika virus levels and provided partial protection in infected mice.
Researchers designed and created proteins that mimicked different surface features of HIV, inducing rabbits to develop antibodies that could bind with the virus. The study provides a novel way to design proteins for vaccines, potentially paving the way for developing a vaccine for HIV.
Researchers found that Human Cytomegalovirus (HCMV) has a lower mutation rate than previously believed, contradicting theories of high genetic diversity. This discovery could pave the way for the development of an effective HCMV vaccine.
Researchers analyzed cervical precancers over seven years and found a 21% decline in CIN2+ cases attributed to HPV16/18. The proportion of these cases declined among vaccinated women, suggesting the vaccine's effectiveness in preventing cervical disease.
Researchers create micromotors coated with red blood cell membranes and titanium dioxide that target the mucus layer of the intestine, stimulating a broader immune response. The oral vaccines successfully delivered in mice, producing ten times more IgA antibodies against Staphylococcal α-toxin than static particles.
Pol Besenius will develop fully synthetic vaccines using modular molecular building blocks to overcome stability and shelf life issues. The SUPRAVACC project aims to create immunological protection against bacterial diseases and anti-tumor vaccines.
A TGen-led study has identified a specific non-polio enterovirus, EV-D68, as the potential cause of an outbreak of Acute Flaccid Myelitis (AFM) among children in Phoenix. The finding is significant as it provides evidence for the need to develop preventative measures, such as new vaccines.
A new long-acting contraceptive designed for self-administration via microneedle patch technology has shown promise in animal testing, providing a therapeutic level of contraception for over a month with a single application. The experimental patch uses biodegradable polymers to slowly release the contraceptive hormone levonorgestrel.
A team of researchers from the University of Copenhagen has successfully completed a phase one clinical trial of their malaria vaccine, demonstrating its safety and ability to induce the desired antibody response in humans. The vaccine is now poised for further testing and potential use in vulnerable populations.
Scientists have developed a new vaccine against the Zika virus, which can prevent microcephaly and other serious conditions in unborn babies. The vaccine is based on the yellow fever vaccine and offers complete protection.
Researchers developed a versatile vaccine effective in mice against Powassan virus and other tick-transmitted flaviviruses. The mRNA-based vaccine platform shows promise for rapid production of vaccines against emerging flaviviruses.
The Wyss Institute aims to develop 'Time-Tolerant Biostasis Therapeutics' that slow down critical processes in the human body, giving time to repair life-threatening injuries. The goal is to stabilize molecules, cells, organs, and metabolic state using temperature-independent mechanisms.